DSS
MCID: DNG001
MIFTS: 43

Dengue Shock Syndrome (DSS)

Categories: Infectious diseases

Aliases & Classifications for Dengue Shock Syndrome

MalaCards integrated aliases for Dengue Shock Syndrome:

Name: Dengue Shock Syndrome 12 55 15 72
Dss 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050125
UMLS 72 C0376300

Summaries for Dengue Shock Syndrome

Disease Ontology : 12 A dengue disease that involves the most severe form of dengue fever, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted by Aedes mosquito bite. The infection has symptom easy bruising, has symptom blood spots, has symptom bleeding gums, and has symptom nosebleeds. It is accompanied by circulatory collapse, involves hypotension, narrow pulse pressure (less than or equal to 20mm Hg), or frank shock. The shock occurs after two to six days of symptoms, followed by collapse, weak pulse, and blueness around the mouth.

MalaCards based summary : Dengue Shock Syndrome, also known as dss, is related to colitis and ulcerative colitis, and has symptoms including easy bruising, blood spots and bleeding gums. An important gene associated with Dengue Shock Syndrome is THBD (Thrombomodulin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Human cytomegalovirus infection. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include endothelial, liver and t cells.

Related Diseases for Dengue Shock Syndrome

Diseases related to Dengue Shock Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 315)
# Related Disease Score Top Affiliating Genes
1 colitis 32.0 TNF IL6 IL1B
2 ulcerative colitis 31.3 TNF IL6 IL1B
3 crohn's colitis 30.6 TNF IL1B
4 exanthem 30.5 TNF IL6 IL1RN
5 intestinal disease 30.3 TNF IL6 IL1B
6 cardiogenic shock 30.3 TNF IL6
7 acute respiratory distress syndrome 30.2 TNF IL6 IL1B
8 autoimmune disease 30.1 TNF IL6 IL1B HLA-DRB1
9 perinatal necrotizing enterocolitis 30.0 TNF IL6 IL1B
10 appendicitis 29.9 TNF IL6 IL1B
11 toxic shock syndrome 29.9 TNF IL6 IL1B
12 gastrointestinal system disease 29.9 TNF IL6 IL1B
13 purpura 29.9 TNF THBD IL6
14 dengue hemorrhagic fever 29.8 TNF IL6 HLA-DRB1 HLA-A CMA1
15 cystitis 29.3 TNF IL6 CCL2
16 pulmonary disease, chronic obstructive 29.0 TNF IL6 CCL2
17 proteasome-associated autoinflammatory syndrome 1 28.9 TNF IL6 IL1RN IL1B CCL2
18 peritonitis 28.9 TNF IL6 IL1B CCL2
19 bacterial infectious disease 28.8 TNF IL6 IL1B CCL2
20 multiple sclerosis 28.4 TNF IL6 IL1B HLA-DRB1 CCL2
21 human immunodeficiency virus type 1 28.4 TNF IL6 HLA-A CCL2
22 diabetes mellitus 28.0 TNF IL6 IL1RN IL1B HLA-DRB1 HLA-A
23 malaria 26.3 TNF THBD IL6 IL1RN IL1B HLA-DRB1
24 dengue disease 12.5
25 dengue virus 11.8
26 hypertrophic neuropathy of dejerine-sottas 11.5
27 46,xy sex reversal 2 11.5
28 neuropathy, congenital hypomyelinating, 1, autosomal recessive 11.4
29 neuropathy, congenital hypomyelinating, 2 11.4
30 charcot-marie-tooth disease, demyelinating, type 4f 11.2
31 inflammatory bowel disease 11.0
32 exudative glomerulonephritis 10.5 TNF IL1B
33 schnitzler syndrome 10.5 IL1RN IL1B
34 colorectal cancer 10.5
35 pustulosis of palm and sole 10.5 TNF IL1RN
36 scleral disease 10.5 TNF IL1RN
37 staphylococcal toxic shock syndrome 10.5 TNF IL1B
38 cryopyrin-associated periodic syndrome 10.4 IL6 IL1RN
39 diarrhea 10.4
40 recurrent corneal erosion 10.4 IL6 IL1B
41 acute cholangitis 10.4 IL6 IL1RN
42 bagassosis 10.4 IL6 IL1B
43 kashin-beck disease 10.4 TNF IL1B
44 crohn's disease 10.4
45 scorpion envenomation 10.4 TNF IL6
46 periodontitis, chronic 10.4 IL6 IL1B
47 mesial temporal lobe epilepsy with hippocampal sclerosis 10.4 IL1B HLA-DRB1
48 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 TNF IL6
49 haemophilus influenzae 10.3 TNF IL1B
50 uremic pruritus 10.3 IL6 IL1B

Graphical network of the top 20 diseases related to Dengue Shock Syndrome:



Diseases related to Dengue Shock Syndrome

Symptoms & Phenotypes for Dengue Shock Syndrome

Symptoms:

12
  • easy bruising
  • blood spots
  • bleeding gums
  • nosebleeds

Drugs & Therapeutics for Dengue Shock Syndrome

Drugs for Dengue Shock Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6 774
2
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
3 Neurotransmitter Agents Phase 4
4 Anti-Allergic Agents Phase 4
5 Histamine H1 Antagonists Phase 4
6 Histamine Antagonists Phase 4
7 Dermatologic Agents Phase 4
8 Antipruritics Phase 4
9
Histamine Phosphate Phase 4 51-74-1 65513
10 Pharmaceutical Solutions Phase 3
11
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
12 Gastrointestinal Agents Phase 1
13 Antacids Phase 1
14 Immunologic Factors Phase 1
15 Adjuvants, Immunologic Phase 1
16 Anti-Ulcer Agents Phase 1
17 Vaccines Phase 1

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN) Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 The Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as a Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
3 The Clinical Efficacy and Safety of a Proprietary Solution Containing Hypertonic Sodium Lactate (Totilac®) Infusion for Resuscitation of Patients With Hemorrhagic Shock Due to Multiple Injuries Completed NCT01433276 Phase 3 Hyperosmolar sodium lactate;Ringer's lactate
4 Phase 1, Placebo-Controlled, Double-Blind, Safety Study of HBV-001 D1 in Healthy Adults Completed NCT00936429 Phase 1
5 Phase 1 Study of the Safety and Immunogenicity of rDEN3/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3 Completed NCT00375726 Phase 1
6 Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-4995, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4 Completed NCT00322946 Phase 1
7 Safety and Immunogenicity of a 2-Dose Regimen of rDEN2/4Δ30 Dengue Vaccine With Boosting at 4 Versus 6 Months Completed NCT00920517 Phase 1
8 A Phase 1 Study To Evaluate The Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue (Serotype 1, 2, 3, and 4) Plasmid DNA Vaccine (TVDV) Formulated With and Without Vaxfectin® Completed NCT01502358 Phase 1
9 Phase 1 Study of the Safety and Immunogenicity of rDEN2/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 2 Completed NCT00094705 Phase 1
10 Phase I Study of the Safety and Immunogenicity of rDEN1delta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 1 Completed NCT00089908 Phase 1
11 Safety and Immunogenicity of a 2-Dose Regimen of rDEN1delta30 Dengue Serotype 1 Vaccine With Boosting at 4 Versus 6 Months Completed NCT00473135 Phase 1
12 Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-200,201, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4 Completed NCT00270699 Phase 1
13 A Phase I Evaluation of the Safety and Immunogenicity of the rDEN1∆30 Dengue Serotype 1 Vaccine Given at a Single Dose of 101 PFU in Healthy Flavivirus-naïve Adult Subjects Completed NCT01084291 Phase 1
14 A Phase I Evaluation of the Safety and Immunogenicity of rDEN2/4 Δ30(ME) Dengue Serotype 2 Vaccine Given at 10^1 PFU in Healthy Flavivirus-naïve Adult Subjects Completed NCT01073306 Phase 1
15 A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3delta30/31‐7164, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3 Completed NCT00831012 Phase 1
16 Evaluation of the Safety and Immunogenicity of Heterologous Dengue Vaccine Administration in Dengue Immune Individuals Completed NCT00458120 Phase 1
17 A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-Naïve Adult Subjects Completed NCT01436422 Phase 1
18 A Phase 1 Evaluation of the Safety and Immunogenicity of Five Admixtures of TetraVax-DV, a Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine, in Healthy Flavivirus-naïve Adult Subjects Completed NCT01072786 Phase 1
19 Phase I Evaluation of the Safety and Immunogenicity of rDEN4delta30 Lot# 109A, a Live Attenuated DEN4 Vaccine, in Healthy Flavivirus-naïve Adult Volunteers. Completed NCT00919178 Phase 1
20 Factors Associated With Poor Dengue Outcomes in Malaysia Completed NCT02510690
21 Adult Dengue Platelet Study Completed NCT01030211
22 The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia Completed NCT02510638
23 Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection Recruiting NCT00688389
24 Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore Recruiting NCT04048837

Search NIH Clinical Center for Dengue Shock Syndrome

Genetic Tests for Dengue Shock Syndrome

Anatomical Context for Dengue Shock Syndrome

MalaCards organs/tissues related to Dengue Shock Syndrome:

41
Endothelial, Liver, T Cells, Monocytes, Kidney, Testes, B Cells

Publications for Dengue Shock Syndrome

Articles related to Dengue Shock Syndrome:

(show top 50) (show all 966)
# Title Authors PMID Year
1
Elevated soluble thrombomodulin in the febrile stage related to patients at risk for dengue shock syndrome. 9 38
17006283 2006
2
Recombinant non-structural 1 (NS1) protein of dengue-2 virus interacts with human STAT3beta protein. 9 38
15878791 2005
3
Cytokine patterns during dengue shock syndrome. 9 38
14656693 2003
4
The role of cytokines in activation of coagulation and fibrinolysis in dengue shock syndrome. 9 38
11858187 2002
5
Serine protease inhibitor AEBSF reduces dengue virus infection via decreased cholesterol synthesis. 38
31386864 2019
6
Impact of population displacement and forced movements on the transmission and outbreaks of Aedes-borne viral diseases: Dengue as a model. 38
31226251 2019
7
Dengue Virus M Protein Promotes NLRP3 Inflammasome Activation to Induce Vascular Leakage in Mice. 38
31413130 2019
8
Dengue vaccine development: Global and Indian scenarios. 38
30684747 2019
9
[Travel Related Fever and Rash: Two Cases of Dengue Fever]. 38
31414637 2019
10
Severe Dengue and Associated Hemophagocytic Lymphohistiocytosis in PICU. 38
31353429 2019
11
Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children. 38
31334842 2019
12
Myocarditis Prevalence in Paediatric Dengue Infection: A Prospective Study in Tertiary Hospital in Yogyakarta, Indonesia. 38
31006000 2019
13
Prostasin Impairs Epithelial Growth Factor Receptor Activation to Suppress Dengue Virus Propagation. 38
30476206 2019
14
Increased Carotid Intima-Media Thickness in Children with a History of Dengue Hemorrhagic Fever. 38
30675845 2019
15
Protein Disulfide Isomerase Inhibitor Suppresses Viral Replication and Production during Antibody-Dependent Enhancement of Dengue Virus Infection in Human Monocytic Cells. 38
30781856 2019
16
Circulation of single serotype of Dengue Virus (DENV-3) in New Delhi, India during 2016: A change in the epidemiological trend. 38
30274896 2019
17
Zika Virus Induced More Severe Inflammatory Response Than Dengue Virus in Chicken Embryonic Livers. 38
31191474 2019
18
Clinical Characteristic and Risk Factors of Acute Kidney Injury among Dengue Viral Infections in Adults: A Retrospective Analysis. 38
30814788 2019
19
Selection-based design of in silico dengue epitope ensemble vaccines. 38
29931821 2019
20
3-Trifluoromethylpyrazolones derived nucleosides: Synthesis and antiviral evaluation. 38
30929566 2019
21
Clinical Course and Management of Dengue in Children Admitted to Hospital; A 5 Years Prospective Cohort Study in Jakarta, Indonesia. 38
30640199 2019
22
Need for guidelines for the combined management of pregnancy and dengue: a retrospective study from an Indian tertiary care maternity hospital. 38
30270767 2019
23
[Winners of globalization: dengue viruses and Japanese encephalitis virus-Diseases in neurology]. 38
30251003 2018
24
Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin. 38
29768710 2018
25
Plectin is Required for Trans-Endothelial Permeability: A Model of Plectin Dysfunction in Human Endothelial Cells After TNF-α Treatment and Dengue Virus Infection. 38
30365215 2018
26
Immune-mediated neurological manifestations of dengue virus- a study of clinico-investigational variability, predictors of neuraxial involvement, and outcome with the role of immunomodulation. 38
30504556 2018
27
Baseline Characterization of Dengue Epidemiology in Yogyakarta City, Indonesia, before a Randomized Controlled Trial of Wolbachia for Arboviral Disease Control. 38
30226138 2018
28
Let-7e inhibits TNF-α expression by targeting the methyl transferase EZH2 in DENV2-infected THP-1 cells. 38
29768655 2018
29
Dengue shock syndrome complicated with acute liver failure and kidney injury, infective endocarditis, and deep vein thrombosis: a case report. 38
30373645 2018
30
Synergism between the tyrosine kinase inhibitor sunitinib and Anti-TNF antibody protects against lethal dengue infection. 38
30071205 2018
31
Hospital-based Surveillance: Accuracy, Adequacy, and Timeliness of Dengue Case Report in Bandung, West Java, Indonesia of 2015. 38
30581261 2018
32
Use of structural equation models to predict dengue illness phenotype. 38
30273334 2018
33
Host Genetic Polymorphisms Influencing Susceptibility to Dengue. 38
30113225 2018
34
Dengue fever as a cause of perimyocarditis and low-pressure cardiac tamponade. 38
30948988 2018
35
Serum fatty acids and progression from dengue fever to dengue haemorrhagic fever/dengue shock syndrome. 38
30105961 2018
36
Evaluation of cell-surface displayed synthetic consensus dengue EDIII cells as a potent oral vaccine candidate. 38
30217208 2018
37
New Onset Diabetes Mellitus in Dengue Shock Syndrome. 38
31324104 2018
38
Circulation of dengue serotypes in the Union Territory of Dadra & Nagar Haveli (India). 38
29988334 2018
39
Role of mitogen-activated protein kinase signaling in the pathogenesis of dengue virus infection. 38
29753850 2018
40
Endogenous gene selection for relative quantification PCR and IL6 transcript levels in the PBMC's of severe and non-severe dengue cases. 38
30071880 2018
41
Early Detection of Plasma Leakage in Dengue Hemorrhagic Fever. 38
30333266 2018
42
Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate. 38
30037331 2018
43
Identification of Compound-B, a novel anti-dengue virus agent targeting the non-structural protein 4A. 38
29758236 2018
44
The Dengue virus in Nepal: gaps in diagnosis and surveillance. 38
30008269 2018
45
Allosteric ligands for the pharmacologically important Flavivirus target (NS5) from ZINC database based on pharmacophoric points, free energy calculations and dynamics correlation. 38
29677482 2018
46
Emergence of dengue in Nepal. 38
29911144 2018
47
Dengue fever with encephalitis: a rare phenomenon. 38
29909394 2018
48
Reversible splenial lesion syndrome associated with dengue fever: a case report. 38
29945676 2018
49
Dengue fever in renal allograft recipients: Clinical course and outcome. 38
29512853 2018
50
Cerebral vasculitis and lateral rectus palsy - two rare central nervous system complications of dengue fever: two case reports and review of the literature. 38
29669602 2018

Variations for Dengue Shock Syndrome

Expression for Dengue Shock Syndrome

Search GEO for disease gene expression data for Dengue Shock Syndrome.

Pathways for Dengue Shock Syndrome

Pathways related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.26 TNF IL6 IL1RN IL1B HLA-DRB1 HLA-A
2
Show member pathways
12.87 TNF MICB IL6 IL1B HLA-A CCL2
3
Show member pathways
12.8 TNF IL6 IL1B HLA-DRB1 HLA-A
4
Show member pathways
12.52 TNF IL6 IL1B HLA-DRB1
5
Show member pathways
12.51 TNF IL6 IL1B CCL2
6 12.49 TNF IL1RN IL1B CCL2
7 12.3 TNF IL6 HLA-DRB1 HLA-A
8
Show member pathways
12.28 TNF IL6 IL1B CCL2
9
Show member pathways
12.28 TNF IL6 IL1B CCL2
10
Show member pathways
12.19 TNF IL6 IL1B HLA-A
11 12.18 TNF IL6 IL1B HLA-DRB1
12
Show member pathways
12.16 TNF IL6 IL1RN IL1B
13 12.12 TNF IL6 IL1RN IL1B
14
Show member pathways
12.1 TNF IL6 IL1B
15 12.01 TNF THBD IL1B CCL2
16
Show member pathways
11.98 TNF IL6 IL1B
17
Show member pathways
11.97 TNF IL6 IL1B
18
Show member pathways
11.92 IL1B HLA-DRB1 HLA-A
19 11.92 TNF IL6 IL1B CCL2
20 11.88 TNF IL6 IL1B CCL2
21 11.86 TNF IL6 IL1B CCL2
22 11.85 TNF IL6 IL1B
23
Show member pathways
11.84 TPSAB1 TNF CMA1
24 11.78 TNF IL6 IL1B HLA-DRB1
25 11.72 TNF IL6 IL1B
26 11.69 TNF IL6 IL1B HLA-DRB1 CCL2
27
Show member pathways
11.63 TNF IL6 IL1B
28 11.63 TNF THBD IL6 IL1B
29 11.56 TNF IL6 IL1B
30 11.51 TNF IL6 IL1RN IL1B CCL2
31 11.49 TNF IL1B CCL2
32 11.45 TNF IL6 IL1B
33 11.4 TNF IL6 IL1B CCL2
34 11.35 TNF IL6 IL1B CMA1 CCL2
35 11.33 TNF IL6 IL1B
36 11.31 TNF IL6 IL1B
37 11.28 THBD IL6 CCL2
38 11.24 TNF IL6 IL1B
39 11.22 TNF IL6 IL1B
40 11.13 TNF IL6 IL1B HLA-DRB1
41 11.1 IL1B CCL2
42 11.1 TNF THBD PLCE1 IL6 IL1B CCL2
43 11.06 TNF PLCE1 IL6 IL1B CCL2
44 11.04 TNF IL6
45 11.04 TNF IL1B
46 11.04 TNF IL6 IL1RN IL1B CCL2
47 10.97 TNF IL6
48 10.96 TNF PLCE1 IL6 IL1B CCL2
49 10.86 TNF IL1B CCL2

GO Terms for Dengue Shock Syndrome

Cellular components related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 TPSAB1 TNF IL6 IL1RN IL1B CMA1
2 cell surface GO:0009986 9.35 TNF THBD MICB HLA-DRB1 HLA-A
3 extracellular space GO:0005615 9.23 TPSAB1 TNF THBD IL6 IL1RN IL1B

Biological processes related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.89 TNF IL6 IL1RN IL1B CCL2
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 TNF IL6 IL1B
3 cytokine-mediated signaling pathway GO:0019221 9.83 TNF IL6 IL1RN IL1B CCL2
4 activation of MAPK activity GO:0000187 9.81 TNF PLCE1 IL1B
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.8 TNF IL6 IL1B
6 positive regulation of JNK cascade GO:0046330 9.79 TNF IL1RN IL1B
7 neutrophil chemotaxis GO:0030593 9.79 IL1RN IL1B CCL2
8 cellular response to organic cyclic compound GO:0071407 9.77 TNF IL1B CCL2
9 humoral immune response GO:0006959 9.75 TNF IL6 CCL2
10 protein kinase B signaling GO:0043491 9.69 TNF IL1B CCL2
11 positive regulation of chemokine production GO:0032722 9.65 TNF IL6
12 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.65 TNF IL1B
13 lipopolysaccharide-mediated signaling pathway GO:0031663 9.65 TNF IL1B CCL2
14 cellular response to lipopolysaccharide GO:0071222 9.65 TNF IL6 IL1RN IL1B CCL2
15 negative regulation of lipid catabolic process GO:0050995 9.64 TNF IL1B
16 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.64 TNF IL1B
17 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.63 TNF IL1B
18 negative regulation of neurogenesis GO:0050768 9.63 TNF IL6 IL1B
19 positive regulation of interleukin-6 production GO:0032755 9.62 TNF IL6 IL1RN IL1B
20 negative regulation of lipid storage GO:0010888 9.61 TNF IL6
21 positive regulation of chemokine biosynthetic process GO:0045080 9.6 TNF IL1B
22 regulation of establishment of endothelial barrier GO:1903140 9.58 TNF IL1B
23 positive regulation of glial cell proliferation GO:0060252 9.58 TNF IL6 IL1B
24 positive regulation of fever generation GO:0031622 9.57 TNF IL1B
25 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.56 IL6 IL1RN
26 sequestering of triglyceride GO:0030730 9.55 TNF IL1B
27 response to glucocorticoid GO:0051384 9.54 TNF IL6 IL1RN
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.52 TNF IL1B
29 positive regulation of neuroinflammatory response GO:0150078 9.33 TNF IL6 IL1B
30 positive regulation of JUN kinase activity GO:0043507 9.24 TNF
31 immune response GO:0006955 9.23 TNF MICB IL6 IL1RN IL1B HLA-DRB1
32 chronic inflammatory response to antigenic stimulus GO:0002439 8.65 TNF

Molecular functions related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 TNF IL6 IL1RN IL1B CCL2
2 interleukin-1 receptor binding GO:0005149 8.96 IL1RN IL1B

Sources for Dengue Shock Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....